Driven by Solving Kids’ Cancer’s deeply rooted belief in the benefits of collaborative research efforts and using our established international footprint, we played a pivotal role – particularly through the advocacy work of Donna Ludwinski - in bringing together American NCI PPTC and European ITCC-P4 paediatric preclinical research consortiums together for the first time ever via the Pediatric Cancer Working Group at the AACR Annual Meeting in Chicago in April 2018.

This unique collaborative session, details of which can be found here, was co-sponsored by us in partnership with Solving Kids’ Cancer (US).

In September 2018, alongside Solving Kids’ Cancer (US) and Neuroblastoma UK, we co-sponsored the ITCC-P4 International Workshop: Improving pediatric oncology drug development through preclinical research in Amsterdam. The purpose of this meeting is to continue the transatlantic collaborative work, seeking to address "the need to define an international scientific consensus on preclinical evaluation to facilitate and improve new anticancer drug development for children and adolescents in the currently changing international regulatory environment.”

Whilst focusing primarily on driving forward and funding clinical research to bring new and innovative treatment options to children in the UK with neuroblastoma today through, at Solving Kids’ Cancer we also recognise that our goal of more effective and safer treatments may be best achieved through the undertaking of rigorous and scientifically robust preclinical testing to identify those most promising new agents to move as quickly as possible through into the clinic.

Moreover, the international collaborative approach that we seek to foster in terms of clinical research can equally be applied in preclinical work. The first truly international collaborative research effort would be one that sees collective input during every aspect of the research process, from preclinical testing, through translation, clinical trial design and development, to the patient getting enrolled and treated in the hospital.


The NCI PPTC (Pediatric Preclinical Testing Consortium) addresses key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions.

The primary objective of the PPTC is to produce reliable preclinical and in-vivo data using genomically characterised patient-derived xoenograft lines so that childhood cancer clinical researchers can better prioritise which agents to pursue in clinical trials. Effective prioritisation of truly active agents for paediatric clinical testing is essential to future success in identifying more effective treatments for children with cancer.

Source. PPTC Overview


Started in 2017, ITCC-P4 (Innovative Therapies for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform) is a newly formed public-private partnership supported by the European consortium ‘Innovative Medicines Initiative’ (IMI).

The consortium with currently 21 partners from eight countries aims to establish 400 new patient-derived preclinical models of high-risk pediatric solid tumours which will be fully characterised (molecularly, immunologically, pharmacologically and clinically well-annotated) and to build a sustainable comprehensive platform to use these models for drug testing. It brings together many of Europe's most distinguished academic and clinical research institutions, well established Small-to-Medium sized Enterprises (SMEs), members of the European Biopharmaceutical Enterprises (EBE) and the members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), thus providing a unique setting to improve patient outcomes by introducing new and effective medicines in standard of care of young people still dying of these rare cancers.

Source. ITCC-P4 Homepage